187 related articles for article (PubMed ID: 18583568)
1. Targeting MEK/MAPK signal transduction module potentiates ATO-induced apoptosis in multiple myeloma cells through multiple signaling pathways.
Lunghi P; Giuliani N; Mazzera L; Lombardi G; Ricca M; Corradi A; Cantoni AM; Salvatore L; Riccioni R; Costanzo A; Testa U; Levrero M; Rizzoli V; Bonati A
Blood; 2008 Sep; 112(6):2450-62. PubMed ID: 18583568
[TBL] [Abstract][Full Text] [Related]
2. Arsenic trioxide-mediated growth inhibition of myeloma cells is associated with an extrinsic or intrinsic signaling pathway through activation of TRAIL or TRAIL receptor 2.
Wu X; Shi J; Wu Y; Tao Y; Hou J; Meng X; Hu X; Han Y; Jiang W; Tang S; Zangari M; Tricot G; Zhan F
Cancer Biol Ther; 2010 Dec; 10(11):1201-14. PubMed ID: 20953137
[TBL] [Abstract][Full Text] [Related]
3. Realgar nanoparticles versus ATO arsenic compounds induce in vitro and in vivo activity against multiple myeloma.
Cholujova D; Bujnakova Z; Dutkova E; Hideshima T; Groen RW; Mitsiades CS; Richardson PG; Dorfman DM; Balaz P; Anderson KC; Jakubikova J
Br J Haematol; 2017 Dec; 179(5):756-771. PubMed ID: 29048129
[TBL] [Abstract][Full Text] [Related]
4. Arsenic trioxide-induced apoptosis in myeloma cells: p53-dependent G1 or G2/M cell cycle arrest, activation of caspase-8 or caspase-9, and synergy with APO2/TRAIL.
Liu Q; Hilsenbeck S; Gazitt Y
Blood; 2003 May; 101(10):4078-87. PubMed ID: 12531793
[TBL] [Abstract][Full Text] [Related]
5. Treatment with arsenic trioxide (ATO) and MEK1 inhibitor activates the p73-p53AIP1 apoptotic pathway in leukemia cells.
Lunghi P; Costanzo A; Levrero M; Bonati A
Blood; 2004 Jul; 104(2):519-25. PubMed ID: 15031205
[TBL] [Abstract][Full Text] [Related]
6. Combined inhibition of the PI3K/mTOR/MEK pathway induces Bim/Mcl-1-regulated apoptosis in pancreatic cancer cells.
Burmi RS; Maginn EN; Gabra H; Stronach EA; Wasan HS
Cancer Biol Ther; 2019; 20(1):21-30. PubMed ID: 30261145
[TBL] [Abstract][Full Text] [Related]
7. Arsenic trioxide induces p53-dependent apoptotic signals in myeloma cells with SiRNA-silenced p53: MAP kinase pathway is preferentially activated in cells expressing inactivated p53.
Kircelli F; Akay C; Gazitt Y
Int J Oncol; 2007 Apr; 30(4):993-1001. PubMed ID: 17332940
[TBL] [Abstract][Full Text] [Related]
8. P38 MAPK inhibition enhancing ATO-induced cytotoxicity against multiple myeloma cells.
Wen J; Cheng HY; Feng Y; Rice L; Liu S; Mo A; Huang J; Zu Y; Ballon DJ; Chang CC
Br J Haematol; 2008 Jan; 140(2):169-80. PubMed ID: 18173754
[TBL] [Abstract][Full Text] [Related]
9. Arsenic trioxide selectively induces early and extensive apoptosis via the APO2/caspase-8 pathway engaging the mitochondrial pathway in myeloma cells with mutant p53.
Akay C; Gazitt Y
Cell Cycle; 2003; 2(4):358-68. PubMed ID: 12851490
[TBL] [Abstract][Full Text] [Related]
10. Effects of arsenic trioxide alone and in combination with bortezomib in multiple myeloma RPMI 8266 cells.
Elmahi AY; Niu C; Li W; Li D; Wang GJ; Hao SS; Cui JW
Asian Pac J Cancer Prev; 2013; 14(11):6469-73. PubMed ID: 24377552
[TBL] [Abstract][Full Text] [Related]
11. Arsenic trioxide augments Chk2/p53-mediated apoptosis by inhibiting oncogenic Wip1 phosphatase.
Yoda A; Toyoshima K; Watanabe Y; Onishi N; Hazaka Y; Tsukuda Y; Tsukada J; Kondo T; Tanaka Y; Minami Y
J Biol Chem; 2008 Jul; 283(27):18969-79. PubMed ID: 18482988
[TBL] [Abstract][Full Text] [Related]
12. Arsenic trioxide-enhanced, matrine-induced apoptosis in multiple myeloma cell lines.
Yu Q; Chen B; Zhang X; Qian W; Ye B; Zhou Y
Planta Med; 2013 Jun; 79(9):775-81. PubMed ID: 23700110
[TBL] [Abstract][Full Text] [Related]
13. Sustained activation of c-jun-N-terminal kinase plays a critical role in arsenic trioxide-induced cell apoptosis in multiple myeloma cell lines.
Kajiguchi T; Yamamoto K; Iida S; Ueda R; Emi N; Naoe T
Cancer Sci; 2006 Jun; 97(6):540-5. PubMed ID: 16734734
[TBL] [Abstract][Full Text] [Related]
14. Metformin potentiates the effect of arsenic trioxide suppressing intrahepatic cholangiocarcinoma: roles of p38 MAPK, ERK3, and mTORC1.
Ling S; Xie H; Yang F; Shan Q; Dai H; Zhuo J; Wei X; Song P; Zhou L; Xu X; Zheng S
J Hematol Oncol; 2017 Feb; 10(1):59. PubMed ID: 28241849
[TBL] [Abstract][Full Text] [Related]
15. Synergistic effect of arsenic trioxide and flt3 inhibition on cells with flt3 internal tandem duplication.
Takahashi S; Harigae H; Yokoyama H; Ishikawa I; Abe S; Imaizumi M; Sasaki T; Kaku M
Int J Hematol; 2006 Oct; 84(3):256-61. PubMed ID: 17050201
[TBL] [Abstract][Full Text] [Related]
16. BH3-only proteins Noxa, Bmf, and Bim are necessary for arsenic trioxide-induced cell death in myeloma.
Morales AA; Gutman D; Lee KP; Boise LH
Blood; 2008 May; 111(10):5152-62. PubMed ID: 18354037
[TBL] [Abstract][Full Text] [Related]
17. Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells.
Yu C; Krystal G; Varticovksi L; McKinstry R; Rahmani M; Dent P; Grant S
Cancer Res; 2002 Jan; 62(1):188-99. PubMed ID: 11782377
[TBL] [Abstract][Full Text] [Related]
18. Enhanced antimyeloma cytotoxicity by the combination of arsenic trioxide and bortezomib is further potentiated by p38 MAPK inhibition.
Wen J; Feng Y; Huang W; Chen H; Liao B; Rice L; Preti HA; Kamble RT; Zu Y; Ballon DJ; Chang CC
Leuk Res; 2010 Jan; 34(1):85-92. PubMed ID: 19608275
[TBL] [Abstract][Full Text] [Related]
19. TRAIL sensitisation by arsenic trioxide is caspase-8 dependent and involves modulation of death receptor components and Akt.
Szegezdi E; Cahill S; Meyer M; O'Dwyer M; Samali A
Br J Cancer; 2006 Feb; 94(3):398-406. PubMed ID: 16434995
[TBL] [Abstract][Full Text] [Related]
20. Indomethacin-enhanced anticancer effect of arsenic trioxide in A549 cell line: involvement of apoptosis and phospho-ERK and p38 MAPK pathways.
Mandegary A; Torshabi M; Seyedabadi M; Amirheidari B; Sharif E; Ghahremani MH
Biomed Res Int; 2013; 2013():237543. PubMed ID: 24312908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
